403 related articles for article (PubMed ID: 21454543)
1. Rac1 protein rescues neurite retraction caused by G2019S leucine-rich repeat kinase 2 (LRRK2).
Chan D; Citro A; Cordy JM; Shen GC; Wolozin B
J Biol Chem; 2011 May; 286(18):16140-9. PubMed ID: 21454543
[TBL] [Abstract][Full Text] [Related]
2. Leucine-rich repeat kinase 2 interacts with p21-activated kinase 6 to control neurite complexity in mammalian brain.
Civiero L; Cirnaru MD; Beilina A; Rodella U; Russo I; Belluzzi E; Lobbestael E; Reyniers L; Hondhamuni G; Lewis PA; Van den Haute C; Baekelandt V; Bandopadhyay R; Bubacco L; Piccoli G; Cookson MR; Taymans JM; Greggio E
J Neurochem; 2015 Dec; 135(6):1242-56. PubMed ID: 26375402
[TBL] [Abstract][Full Text] [Related]
3. GTPase activity and neuronal toxicity of Parkinson's disease-associated LRRK2 is regulated by ArfGAP1.
Stafa K; Trancikova A; Webber PJ; Glauser L; West AB; Moore DJ
PLoS Genet; 2012; 8(2):e1002526. PubMed ID: 22363216
[TBL] [Abstract][Full Text] [Related]
4. Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells.
Plowey ED; Cherra SJ; Liu YJ; Chu CT
J Neurochem; 2008 May; 105(3):1048-56. PubMed ID: 18182054
[TBL] [Abstract][Full Text] [Related]
5. Contribution of GTPase activity to LRRK2-associated Parkinson disease.
Tsika E; Moore DJ
Small GTPases; 2013; 4(3):164-70. PubMed ID: 24025585
[TBL] [Abstract][Full Text] [Related]
6. GTPase activity regulates kinase activity and cellular phenotypes of Parkinson's disease-associated LRRK2.
Biosa A; Trancikova A; Civiero L; Glauser L; Bubacco L; Greggio E; Moore DJ
Hum Mol Genet; 2013 Mar; 22(6):1140-56. PubMed ID: 23241358
[TBL] [Abstract][Full Text] [Related]
7. 14-3-3 Proteins regulate mutant LRRK2 kinase activity and neurite shortening.
Lavalley NJ; Slone SR; Ding H; West AB; Yacoubian TA
Hum Mol Genet; 2016 Jan; 25(1):109-22. PubMed ID: 26546614
[TBL] [Abstract][Full Text] [Related]
8. Kinase activity of mutant LRRK2 manifests differently in hetero-dimeric vs. homo-dimeric complexes.
Leandrou E; Markidi E; Memou A; Melachroinou K; Greggio E; Rideout HJ
Biochem J; 2019 Feb; 476(3):559-579. PubMed ID: 30670570
[TBL] [Abstract][Full Text] [Related]
9. Functional interaction of Parkinson's disease-associated LRRK2 with members of the dynamin GTPase superfamily.
Stafa K; Tsika E; Moser R; Musso A; Glauser L; Jones A; Biskup S; Xiong Y; Bandopadhyay R; Dawson VL; Dawson TM; Moore DJ
Hum Mol Genet; 2014 Apr; 23(8):2055-77. PubMed ID: 24282027
[TBL] [Abstract][Full Text] [Related]
10. The G2385R variant of leucine-rich repeat kinase 2 associated with Parkinson's disease is a partial loss-of-function mutation.
Rudenko IN; Kaganovich A; Hauser DN; Beylina A; Chia R; Ding J; Maric D; Jaffe H; Cookson MR
Biochem J; 2012 Aug; 446(1):99-111. PubMed ID: 22612223
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of excessive mitochondrial fission reduced aberrant autophagy and neuronal damage caused by LRRK2 G2019S mutation.
Su YC; Qi X
Hum Mol Genet; 2013 Nov; 22(22):4545-61. PubMed ID: 23813973
[TBL] [Abstract][Full Text] [Related]
12. Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.
Tsika E; Nguyen AP; Dusonchet J; Colin P; Schneider BL; Moore DJ
Neurobiol Dis; 2015 May; 77():49-61. PubMed ID: 25731749
[TBL] [Abstract][Full Text] [Related]
13. Dependence of leucine-rich repeat kinase 2 (LRRK2) kinase activity on dimerization.
Sen S; Webber PJ; West AB
J Biol Chem; 2009 Dec; 284(52):36346-36356. PubMed ID: 19826009
[TBL] [Abstract][Full Text] [Related]
14. Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations.
Sheng Z; Zhang S; Bustos D; Kleinheinz T; Le Pichon CE; Dominguez SL; Solanoy HO; Drummond J; Zhang X; Ding X; Cai F; Song Q; Li X; Yue Z; van der Brug MP; Burdick DJ; Gunzner-Toste J; Chen H; Liu X; Estrada AA; Sweeney ZK; Scearce-Levie K; Moffat JG; Kirkpatrick DS; Zhu H
Sci Transl Med; 2012 Dec; 4(164):164ra161. PubMed ID: 23241745
[TBL] [Abstract][Full Text] [Related]
15. The G2019S variant of leucine-rich repeat kinase 2 (LRRK2) alters endolysosomal trafficking by impairing the function of the GTPase RAB8A.
Rivero-Ríos P; Romo-Lozano M; Madero-Pérez J; Thomas AP; Biosa A; Greggio E; Hilfiker S
J Biol Chem; 2019 Mar; 294(13):4738-4758. PubMed ID: 30709905
[TBL] [Abstract][Full Text] [Related]
16. LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity.
Jaleel M; Nichols RJ; Deak M; Campbell DG; Gillardon F; Knebel A; Alessi DR
Biochem J; 2007 Jul; 405(2):307-17. PubMed ID: 17447891
[TBL] [Abstract][Full Text] [Related]
17. Pathogenic LRRK2 mutations, through increased kinase activity, produce enlarged lysosomes with reduced degradative capacity and increase ATP13A2 expression.
Henry AG; Aghamohammadzadeh S; Samaroo H; Chen Y; Mou K; Needle E; Hirst WD
Hum Mol Genet; 2015 Nov; 24(21):6013-28. PubMed ID: 26251043
[TBL] [Abstract][Full Text] [Related]
18. Neurite Aggregation and Calcium Dysfunction in iPSC-Derived Sensory Neurons with Parkinson's Disease-Related LRRK2 G2019S Mutation.
Schwab AJ; Ebert AD
Stem Cell Reports; 2015 Dec; 5(6):1039-1052. PubMed ID: 26651604
[TBL] [Abstract][Full Text] [Related]
19. Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2.
Ramonet D; Daher JP; Lin BM; Stafa K; Kim J; Banerjee R; Westerlund M; Pletnikova O; Glauser L; Yang L; Liu Y; Swing DA; Beal MF; Troncoso JC; McCaffery JM; Jenkins NA; Copeland NG; Galter D; Thomas B; Lee MK; Dawson TM; Dawson VL; Moore DJ
PLoS One; 2011 Apr; 6(4):e18568. PubMed ID: 21494637
[TBL] [Abstract][Full Text] [Related]
20. Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants.
Li X; Tan YC; Poulose S; Olanow CW; Huang XY; Yue Z
J Neurochem; 2007 Oct; 103(1):238-47. PubMed ID: 17623048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
